Heterogeneity of quadriceps muscle phenotype in chronic obstructive pulmonary disease (Copd); implications for stratified medicine?
Article first published online: 27 AUG 2013
© 2013 The Authors. Muscle & Nerve published by Wiley Periodicals, Inc.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Muscle & Nerve
Volume 48, Issue 4, pages 488–497, October 2013
How to Cite
Natanek, S. A., Gosker, H. R., Slot, I. G.M., Marsh, G. S., Hopkinson, N. S., Man, W. D.-C., Tal-Singer, R., Moxham, J., Kemp, P. R., Schols, A. M.W.J. and Polkey, M. I. (2013), Heterogeneity of quadriceps muscle phenotype in chronic obstructive pulmonary disease (Copd); implications for stratified medicine?. Muscle Nerve, 48: 488–497. doi: 10.1002/mus.23784
- Issue published online: 23 SEP 2013
- Article first published online: 27 AUG 2013
- Accepted manuscript online: 30 JAN 2013 10:45PM EST
- Manuscript Accepted: 8 JAN 2013
- fiber atrophy;
- fiber shift;
- muscle biopsy;
- muscle histology;
Quadriceps muscle dysfunction is common in COPD. Determining, and, if possible, predicting quadriceps phenotype in COPD is important for patient stratification for therapeutic trials.
In biopsies from 114 COPD patients and 30 controls, we measured fiber size and proportion and assessed the relationship with quadriceps function (strength and endurance), clinical phenotype (lung function, physical activity, fat-free mass) and exercise performance. In a subset (n = 40) we measured muscle mid-thigh cross-sectional area by computed tomography.
Normal ranges for fiber proportions and fiber cross-sectional area were defined from controls; we found isolated fiber shift in 31% of patients, isolated fiber (predominantly type II) atrophy in 20%, both shift and atrophy in 25%, and normal fiber parameters in 24%. Clinical parameters related poorly to muscle biopsy appearances.
Quadriceps morphology is heterogeneous in COPD and cannot be predicted without biopsy, underlining the need for biomarkers. Muscle Nerve 48: 488–497, 2013